Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
Saved in:
| Title: | Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study. |
|---|---|
| Authors: | Colson AE; Community Resource Initiative, Boston, and Cambridge Health Alliance, Cambridge, Massachusetts (A.E.C.)., Crofoot GE; The Crofoot Research Center, Houston, Texas (G.E.C.)., Ruane PJ; Ruane Clinical Research, Los Angeles, California (P.J.R.)., Ramgopal MN; Midway Immunology & Research Center, Fort Pierce, Florida (M.N.R.)., Dretler AW; Metro Infectious Disease Consultants, Decatur, Georgia (A.W.D.)., Nahass RG; IDCare, Hillsborough, New Jersey (R.G.N.)., Sinclair GI; Prism Health North Texas, Dallas, Texas (G.I.S.)., Berhe M; North Texas Infectious Diseases Consultants, Dallas, Texas (M.B.)., Roberts A; Division of Infectious Diseases, George Washington University School of Medicine and Health Sciences, Washington, DC (A.R.)., Applin S; Community Health Care, Tacoma, Washington (S.A.)., Brinson C; Central Texas Clinical Research, Austin, Texas (C.B.)., Jayaweera D; University of Miami, Miller School of Medicine, Miami, Florida (D.J.)., Workowski KA; Department of Medicine, Division of Infectious Diseases, Emory University, Atlanta, Georgia (K.A.W.)., Shihadeh F; Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.)., Liu SY; Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.)., Klopfer S; Merck & Co., Rahway, New Jersey (S.K., C.L., E.G.R.)., Llamoso C; Merck & Co., Rahway, New Jersey (S.K., C.L., E.G.R.)., Madera S; Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.)., Dvory-Sobol H; Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.)., Rhee MS; Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.)., Rhee EG; Merck & Co., Rahway, New Jersey (S.K., C.L., E.G.R.)., Baeten JM; Gilead Sciences, Foster City, California (F.S., S.-Y.L., S.M., H.D.-S., M.S.R., J.M.B.)., Eron JJ; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.J.E.). |
| Source: | Annals of internal medicine [Ann Intern Med] 2026 Feb; Vol. 179 (2), pp. 168-176. Date of Electronic Publication: 2025 Dec 23. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study |
| Journal Info: | Publisher: American College of Physicians--American Society of Internal Medicine Country of Publication: United States NLM ID: 0372351 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1539-3704 (Electronic) Linking ISSN: 00034819 NLM ISO Abbreviation: Ann Intern Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1539-3704 |
|---|---|
| DOI: | 10.7326/ANNALS-25-01939 |
